Regeneron, Biocon Settle Patent Suit on Biosimilar of Eylea Drug

A federal judge lifted an order blocking a biosimilar of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea, approving the drugmaker’s deal ending patent litigation with a pair of rivals.

Judge Thomas S. Kleeh approved the stipulation and order Tuesday in the US District Court for the Northern District of West Virginia, resolving Regeneron’s disputes with Mylan Pharmaceuticals Inc., a unit of Viatris Inc., and Biocon Ltd., which will market its own macular degeneration drug in the US. The order vacated the permanent injunction and dismissed all claims and counterclaims, closing the door on both sides’ chances to renew ...